Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.

@article{Yanik2013SemiquantitativeMS,
  title={Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.},
  author={Gregory Anthony Yanik and Marguerite T. Parisi and Barry L. Shulkin and Arlene H Naranjo and Susan G. Kreissman and Wendy B London and Judith G Villablanca and John M. Maris and Julie Park and Susan L Cohn and Patrick B McGrady and Katherine K. Matthay},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2013},
  volume={54 4},
  pages={541-8}
}
UNLABELLED Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease. METHODS mIBG scans from 280 patients with mIBG-avid, stage 4 neuroblastoma enrolled on the Children's Oncology Group (COG) protocol A3973 were evaluated at diagnosis (n = 280), after induction chemotherapy (n… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
36 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…